Infliximab‐related malignant melanoma and cranial nerves IX and XII palsy secondary to IFN‐α2b therapy

Mir-Bonafé, José M; Fernández‐López, Emilia; Cañueto, Javier; Gil‐Melcón, María; García‐Domínguez, Rocío; Unamuno-Pérez, P. de

doi:10.1111/j.1365-4632.2011.05452.x

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral non‐Hodgkin lymphoma and OSCC development were reported in patients treated with etanercept for RA 34,40 . Oral melanoma was also diagnosed after treatment with infliximab for hidradenitis suppurativa in one patient 41 …”

Section: Resultsmentioning

confidence: 96%

See 1 more Smart Citation

World Workshop on Oral Medicine VII: Oral adverse effects to biologic agents in patients with inflammatory disorders. A scoping review

France

Yogarajah

Gueiros

et al. 2022

J Oral Pathology Medicine

View full text Add to dashboard Cite

Background Biologic agents are rapidly emerging as an effective therapy to treat autoimmune and other chronic diseases. The use of these agents is poorly characterized, resulting in a lack of guidance for dental practitioners. Case reports of oral adverse events have begun to emerge. However, their scope and frequency have not been summarized and analysed to date. The objective of this review was to characterize the literature on oral adverse effects associated with biological therapy when used for autoimmune and inflammatory disorders. Methods This review was developed in accordance with scoping review recommendations. Search strategies were developed and employed for six databases. Studies were selected using a systematic search process but with broad inclusion of study types given the paucity of information available. Reports of oral adverse events were analysed descriptively according to agent, mechanism of action, underlying disease, and oral adverse effect observed. Results Our search returned 2080 articles and 51 met our inclusion criteria, of which most were case reports. The most frequent adverse effects included angioedema, oral lichenoid lesions, osteonecrosis of the jaw, and oral infections. There were also cases of oral malignancies associated with use of biologic agents. Less common effects such as pigmentation were also described. Conclusions Oral adverse events have been reported in patients on biologic therapy, albeit in small numbers to date. This limits the generalizability of these results, which should not be used to generate a clinical guideline as they are based primarily on case reports. However, this study presents the first review characterizing the adverse effects observed. Large multi‐center studies will be necessary to further define the oral and dental complications caused by biologic agents.

show abstract

Section: Resultsmentioning

confidence: 96%

“…34,40 Oral melanoma was also diagnosed after treatment with infliximab for hidradenitis suppurativa in one patient. 41…”

Section: Oral Malignanciesmentioning

confidence: 99%